B01AC16 - search results

Ireland - English - HPRA (Health Products Regulatory Authority)

eptifibatide strides 0.75 mg/ml solution for infusion

generics (uk) limited - eptifibatide - solution for infusion - 0.75 mg/ml - platelet aggregation inhibitors excl. heparin

Ireland - English - HPRA (Health Products Regulatory Authority)

eptifibatide strides 2 mg/ml solution for injection

generics (uk) limited - eptifibatide - solution for injection - 2 mg/ml - platelet aggregation inhibitors excl. heparin

European Union - English - EMA (European Medicines Agency)

eptifibatide accord

accord healthcare s.l.u. - eptifibatide - myocardial infarction - antithrombotic agents - eptifibatide accord is intended for use with acetylsalicylic acid and unfractionated heparin.eptifibatide accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ecg) changes and/or elevated cardiac enzymes.patients most likely to benefit from eptifibatide accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early ptca (percutaneous transluminal coronary angioplasty).

European Union - English - EMA (European Medicines Agency)

integrilin

glaxosmithkline (ireland) limited - eptifibatide - angina, unstable; myocardial infarction - antithrombotic agents - integrilin is intended for use with acetylsalicylic acid and unfractionated heparin.integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ecg changes and / or elevated cardiac enzymes.patients most likely to benefit from integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (ptca).